Tiziana life sciences announces platform presentation of new quantitative pet imaging data on foralumab at the annual meeting of the american academy of neurology

New york, april 11, 2024 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa ) (“tiziana” or the “company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “treatment of pira with nasal foralumab dampens microglial activation and stabilizes clinical progression in non-active secondary progressive ms” that will be presented during the “multiple sclerosis: therapeutics and clinical decision making” session at the annual meeting of the american academy of neurology, to be held april 13-18, 2024 in denver, colorado.
TLSA Ratings Summary
TLSA Quant Ranking